Job title: Chief Scientific Officer
Piet Wigerinck, Ph.D. joined Galapagos in April 2008 as SVP Development and was appointed Chief Scientific Officer in 2010. Under his leadership, Galapagos has developed a large pipeline of novel mechanism of action drugs. He has supervised multiple successful proofs-of-concept patient studies, including filgotinib, GLPG1690, and MOR106.
Prior to his tenure at Galapagos, Piet was Vice President, Drug Discovery, Early Development and CM&C at Tibotec-Virco Comm. VA (a subsidiary of Johnson & Johnson Services, Inc.) Under his leadership at Tibotec, TMC114 (Prezista™) and TMC435 (Olysio™) were selected and moved forward into clinical trials. Piet played a key role in Tibotec’s expansion into novel diseases such as Hepatitis C and advanced several compounds into Phase 1 and Phase 2 clinical trials.
Piet has over 30 years of R&D experience in the pharmaceutical industry and biotechnology. Piet holds a Ph.D. from the K.U. Leuven and is inventor on more than 25 patent applications.
Filgotinib: Maturing the JAK1 Profile 10:00 am
Discussing how JAK1 inhibitors are promising the next generation of anti-inflammatory drugs Growing understanding of JAK1 pharmacology leads to better drugs Exploring how oral drugs can replace many injectables in the inflammatory spaceRead more
day: Bonus Content